Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis.

ABSTRACT:

Background

Multiple sclerosis is an inflammatory and degenerative disease of the central nervous system leading to demyelination and axonal loss. Relapsing-remitting multiple sclerosis (RRMS) is commonly treated by anti-inflammatory drugs, where one of the most effective drugs to date is the monoclonal antibody natalizumab.

Methods

The cerebrospinal fluid (CSF) proteome was analyzed in 56 patients with RRMS before and after natalizumab treatment, using label-free mass spectrometry and a subset of the changed proteins were verified by parallel reaction monitoring in a new cohort of 20 patients, confirming the majority of observed changes.

Results

A total of 287 differentially abundant proteins were detected including (i) the decrease of proteins with roles in immunity,

SUBMITTER: Lereim RR 

PROVIDER: S-EPMC10962820 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature